Fed. Circ. Backs Amgen's $70M Patent Win Over Epogen
The Federal Circuit on Monday affirmed Amgen's $70 million victory over its anemia treatment Epogen, ruling the jury correctly found that Hospira was not shielded by a safe harbor meant for...To view the full article, register now.
Already a subscriber? Click here to view full article